These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24779206)

  • 41. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selected aspects of europeization of pharmaceutical law.
    Zimmermann A; Wengler L; Pawłowski L
    Acta Pol Pharm; 2010; 67(2):205-10. PubMed ID: 20369799
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Orphan drugs in France (2001-2005): access to information and characteristics].
    Baumevieille M; Daveluy A; Aulois-Griot M; Haramburu F
    Therapie; 2007; 62(1):9-16. PubMed ID: 17374342
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Regulations on gases for medical use in France].
    Poitou P; Fouret C; Duffau E
    Ann Pharm Fr; 2002 Sep; 60(5):326-32. PubMed ID: 12378142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Orphan drug regulations. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2013 Jun; 78(113):35117-35. PubMed ID: 23767079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The European Union Policy in the Field of Rare Diseases.
    Moliner AM; Waligora J
    Adv Exp Med Biol; 2017; 1031():561-587. PubMed ID: 29214592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Orphan drug development and the impact on non-medical support groups.
    Manuel J; Collin-Histed T
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():116-24. PubMed ID: 24380130
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Orphan drug legislation: lessons for neglected tropical diseases.
    Villa S; Compagni A; Reich MR
    Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Community requirements relating to drugs derived from human blood and plasma].
    Brunko P
    Ann Pharm Fr; 1994; 52(2):89-98. PubMed ID: 7944184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Orphan drugs. EU regulations.
    Mariz S; Llinares J; Westermark K
    BMJ; 2011 Jan; 342():d136. PubMed ID: 21224321
    [No Abstract]   [Full Text] [Related]  

  • 55. Defining orphan conditions in the context of the European orphan regulation: challenges and evolution.
    O'Connor DJ; Sheean ME; Hofer MP; Tsigkos S; Mariz S; Fregonese L; Larsson K; Hivert V; Westermark K; Naumann-Winter F; Stoyanova-Beninska V; Barišić I; Capovilla G; Magrelli A; Sepodes B
    Nat Rev Drug Discov; 2019 Jul; 18(7):479-480. PubMed ID: 30940922
    [No Abstract]   [Full Text] [Related]  

  • 56. Rare diseases and orphan drugs: Latvian story.
    Logviss K; Krievins D; Purvina S
    Orphanet J Rare Dis; 2014 Sep; 9():147. PubMed ID: 25231378
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The European challenges of funding orphan medicinal products.
    Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
    Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medicinal products in the European Union--between harmonization and divergence.
    Lojko N
    Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.
    Murakami M; Narukawa M
    Drug Discov Today; 2016 Apr; 21(4):544-9. PubMed ID: 26945941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.